Equities Analysts Offer Predictions for JANX FY2026 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Janux Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($4.43) per share for the year. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Other equities research analysts have also issued reports about the company. Scotiabank lowered their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Trading Down 2.6%

NASDAQ:JANX traded down $0.66 during mid-day trading on Tuesday, hitting $24.90. The company's stock had a trading volume of 371,015 shares, compared to its average volume of 868,968. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -21.28 and a beta of 2.96. Janux Therapeutics has a fifty-two week low of $22.48 and a fifty-two week high of $71.71. The stock has a fifty day moving average of $27.02 and a 200-day moving average of $37.04.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of JANX. Russell Investments Group Ltd. increased its stake in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics during the 4th quarter worth about $59,000. GAMMA Investing LLC increased its position in Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares in the last quarter. US Bancorp DE increased its position in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after acquiring an additional 1,658 shares in the last quarter. Finally, FNY Investment Advisers LLC raised its stake in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after acquiring an additional 2,425 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.